Indian pharmaceutical market grows 7.9% in July, led by chronic therapies

The Indian pharmaceutical market recorded a growth of 7.9% in July 2025, driven primarily by positive value growth in major chronic therapies, according to market research firm Pharmarack. Cardiac and antidiabetes therapies, which together represent nearly 25% of the domestic market, posted value growth of 14.1% and 9%, respectively. Other therapy segments, such as urology and antineoplastics, each contributing around 2% to monthly sales, also reported double-digit value increases. Vice-President (Commercial) at Pharmarack, Ms. Sheetal Sapale, noted that price increases and new product launches mainly fuelled this growth despite negligible volume expansion.

The moving annual turnover (MAT) for the Indian pharmaceutical market between August 2024 and July 2025 grew by 7.4%, reaching a total turnover of over Rs. 2,30,000 crore (US$ 26 billion), with a marginal volume increase of 0.4%. Therapy areas, including cardiac, gastrointestinal, and anti-infectives, comprising about 37% of the pharmaceutical market, showed robust volume growth of 10.7%, 10.1%, and 6.5%, respectively. While most leading companies experienced modest value growth in July, firms like Corona (15.8%), Ajanta (14%), Bayer (13.4%), Glenmark (12.9%), and Sun Pharma (12.6%) reported significant gains. USV’s anti-diabetic drug Glycomet GP and Himalaya’s Liv 52 remained the top-selling brands with sales of Rs. 80 crore (US$ 9.1 million) and Rs. 74 crore (US$ 8.4 million), respectively.

Disclaimer: This information has been collected through secondary research and IBEF is not responsible for any errors in the same.